Annual Drug Patent Expirations for LAMICTAL+XR
Lamictal Xr is a drug marketed by Glaxosmithkline Llc and is included in one NDA. It is available from one supplier. There are two patents protecting this drug and one Paragraph IV challenge.
LAMICTAL XR drug price trends.
Drug patent litigation for LAMICTAL XR.
This drug has eigthy-nine patent family members in thirty-eight countries.
The generic ingredient in LAMICTAL XR is lamotrigine. One supplier is listed for this compound. Additional details are available on the lamotrigine profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
